Proteomics International Wins Canadian Patent for PromarkerEso Esophageal Cancer Test

Proteomics International Laboratories Ltd. ( (AU:PIQ) ) just unveiled an update.

Proteomics International Laboratories has secured a Canadian patent for PromarkerEso, its first-in-class blood test designed for the early diagnosis of esophageal adenocarcinoma, extending intellectual property protection for the test in Canada until November 2035. The patent strengthens the company’s commercialisation pathway in North America by supporting potential direct sales, partnerships and licensing, and complements existing protection in Australia, China, Hong Kong, Europe and the US. Given that esophageal adenocarcinoma is frequently linked to chronic acid reflux, has poor survival rates and is often diagnosed late due to reliance on invasive and costly endoscopy, the company positions PromarkerEso as a highly accurate, less invasive screening tool that could meet a significant unmet clinical need and support its growth in global diagnostics markets.

The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.84 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.

More about Proteomics International Laboratories Ltd.

Proteomics International Laboratories Ltd, a subsidiary of PILL and listed on the ASX, is a Perth-based medical technology company specialising in precision diagnostics and bio-analytical services grounded in proteomics, the large-scale study of proteins. Its portfolio includes proprietary biomarker-based blood tests such as PromarkerEso, developed to improve early detection and management of serious diseases, with a focus on enhancing patient outcomes and reducing healthcare costs globally.

Average Trading Volume: 426,387

Technical Sentiment Signal: Strong Buy

Current Market Cap: A$137.6M

See more data about PIQ stock on TipRanks’ Stock Analysis page.